DE60335915D1 - Myostatin hemmende bindungsstoffe - Google Patents

Myostatin hemmende bindungsstoffe

Info

Publication number
DE60335915D1
DE60335915D1 DE60335915T DE60335915T DE60335915D1 DE 60335915 D1 DE60335915 D1 DE 60335915D1 DE 60335915 T DE60335915 T DE 60335915T DE 60335915 T DE60335915 T DE 60335915T DE 60335915 D1 DE60335915 D1 DE 60335915D1
Authority
DE
Germany
Prior art keywords
myostatin
inhibiting compounds
inhibiting
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335915T
Other languages
German (de)
English (en)
Inventor
Hq Han
Hosung Min
Thomas Charles Boone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE60335915D1 publication Critical patent/DE60335915D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
DE60335915T 2002-12-20 2003-12-19 Myostatin hemmende bindungsstoffe Expired - Lifetime DE60335915D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43592302P 2002-12-20 2002-12-20
PCT/US2003/040781 WO2004058988A2 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin

Publications (1)

Publication Number Publication Date
DE60335915D1 true DE60335915D1 (de) 2011-03-10

Family

ID=32682298

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335915T Expired - Lifetime DE60335915D1 (de) 2002-12-20 2003-12-19 Myostatin hemmende bindungsstoffe

Country Status (27)

Country Link
US (7) US7511012B2 (enExample)
EP (2) EP1581649B1 (enExample)
JP (3) JP4959137B2 (enExample)
KR (9) KR20110086881A (enExample)
CN (2) CN101287484B (enExample)
AR (2) AR042545A1 (enExample)
AT (1) ATE496938T1 (enExample)
AU (2) AU2003301195B2 (enExample)
BR (1) BR0317538A (enExample)
CA (2) CA2510893C (enExample)
CY (1) CY1111388T1 (enExample)
DE (1) DE60335915D1 (enExample)
DK (1) DK1581649T3 (enExample)
EA (1) EA009056B1 (enExample)
ES (1) ES2359562T3 (enExample)
IL (3) IL169168A0 (enExample)
ME (1) MEP57508A (enExample)
MX (1) MXPA05006521A (enExample)
NO (2) NO335982B1 (enExample)
NZ (1) NZ541253A (enExample)
PL (1) PL383616A1 (enExample)
PT (1) PT1581649E (enExample)
RS (1) RS52815B (enExample)
SI (1) SI1581649T1 (enExample)
TW (1) TWI328456B (enExample)
WO (1) WO2004058988A2 (enExample)
ZA (1) ZA200505481B (enExample)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005066204A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
EP1755648A2 (en) * 2004-05-27 2007-02-28 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
MX2007008132A (es) 2004-12-30 2007-07-20 Schering Plough Ltd Vacuna para aumentar el crecimiento basada en epitopes neutralizantes.
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1864139A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of an immune response to gdf-8 modulating agents
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
JP2010512326A (ja) * 2006-12-08 2010-04-22 アクセルロン ファーマ， インコーポレイテッド Ｃｅｒｂｅｒｕｓ、Ｃｏｃｏおよびこれらの誘導体の使用
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009015345A1 (en) * 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
AU2008293425B2 (en) * 2007-08-31 2014-09-18 Amgen Inc. Solid-state protein formulation
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
EP2303311B1 (en) 2008-05-14 2018-08-01 Agriculture Victoria Services Pty Ltd Angiogenin for use in treating skeletal muscle disorders
PE20150680A1 (es) 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
US8945511B2 (en) * 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
PH12013500315A1 (en) 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
WO2012153337A2 (en) * 2011-05-11 2012-11-15 Technion Research & Development Foundation Ltd. Anti-microbial peptides and uses of same
EP3045187B1 (en) 2011-10-14 2019-04-10 Amgen Inc. Injector and method of assembly
AU2012328753A1 (en) 2011-10-26 2014-04-24 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light
FR2982860B1 (fr) * 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire
CA2868469A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
SG11201405841RA (en) 2012-03-26 2014-10-30 Pronutria Inc Nutritive fragments, proteins and methods
HK1206764A1 (en) 2012-03-26 2016-01-15 Axcella Health Inc. Nutritive proteins and methods
EP2831098A4 (en) 2012-03-26 2016-12-07 Axcella Health Inc LOADED NUTRIENT PROTEINS AND METHODS
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
EP4678239A3 (en) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
WO2014119753A1 (ja) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 マイオスタチン阻害ペプチド
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
KR101523065B1 (ko) * 2013-06-19 2015-05-27 한국기초과학지원연구원 입자크기가 제어된 금 나노입자의 제조방법 및 제조된 금 나노입자를 이용한 비색식 강산 검출방법
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
US11268107B2 (en) 2015-04-23 2022-03-08 Washington State University SMAD7 gene delivery into muscle cells
CN106191215B (zh) 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
EP3448414B1 (en) * 2016-04-25 2024-04-17 Five Prime Therapeutics, Inc. Nope for treatment of pathological muscle loss and weakness
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10150115B2 (en) * 2016-07-21 2018-12-11 Spacepharma SA System and method for rehydrating powder and delivering the rehydrated powder to a reactor
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3532127B1 (en) 2016-10-25 2026-04-08 Amgen Inc. On-body injector
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
HRP20230308T1 (hr) * 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR102042352B1 (ko) 2018-07-16 2019-11-07 강릉원주대학교산학협력단 땅콩 껍질 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물
KR102259645B1 (ko) 2018-07-16 2021-06-02 강릉원주대학교산학협력단 구멍쇠미역 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
DK3870957T3 (da) 2018-10-23 2025-09-29 Amgen Inc Automatisk kalibrering og automatisk vedligeholdelse af spectroskopiske modeller til realtidsprediktioner
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
EP3958934B1 (en) 2019-04-24 2025-04-09 Amgen Inc. Syringe sterilization verification assemblies and methods
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2023076318A1 (en) 2021-10-27 2023-05-04 Amgen Inc. Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
KR102726401B1 (ko) * 2021-11-25 2024-11-05 (주)네오크레마 지방전구세포의 증식과 지방세포로의 분화를 억제하는 신규 펩티드 및 이의 용도
US20250082720A1 (en) * 2021-11-25 2025-03-13 Neo Cremar Co., Ltd. New peptide and uses thereof
US20250090626A1 (en) * 2021-11-25 2025-03-20 Neo Cremar Co., Ltd. New peptide and uses thereof
KR102726402B1 (ko) * 2021-11-25 2024-11-05 (주)네오크레마 지방전구세포의 증식과 지방세포로의 분화를 억제하는 신규 펩티드 및 이의 용도
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP0618804A4 (en) * 1991-10-08 1995-06-07 Univ Duke PEPTIDE CORRESPONDING TO ANTIGENIC DETERMINANTS OF THE ACQUIRED IMMUNODEFICITARY SYNDROME HTLV.
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
ES2330062T3 (es) 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
EP1027608B1 (en) * 1998-07-30 2010-01-20 Odyssey Thera, Inc. Protein fragment complementation assays
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003517580A (ja) * 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
EP1593689A3 (en) 2000-01-18 2006-04-05 Ovita Limited Myostatin and mimetics thereof
EP1383793B1 (en) * 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
AU2002248222B2 (en) * 2000-12-23 2006-04-27 Dyax Corp. Fibrin binding polypeptides useful inter alia in medical imaging processes
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
CA2558478A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1

Also Published As

Publication number Publication date
IL205265A0 (en) 2011-07-31
KR20110086881A (ko) 2011-08-01
KR20140004805A (ko) 2014-01-13
CA2510893C (en) 2012-07-10
PL383616A1 (pl) 2008-04-14
US7511012B2 (en) 2009-03-31
EP1581649A4 (en) 2008-10-08
EP2272864A3 (en) 2011-02-16
KR20160045936A (ko) 2016-04-27
DK1581649T3 (da) 2011-05-02
MEP57508A (en) 2011-05-10
PT1581649E (pt) 2011-04-13
US7928075B2 (en) 2011-04-19
JP4959137B2 (ja) 2012-06-20
CA2774928A1 (en) 2004-07-15
KR20130036378A (ko) 2013-04-11
JP2013048622A (ja) 2013-03-14
CN102382172A (zh) 2012-03-21
NO20141479L (no) 2005-09-08
US20130230515A1 (en) 2013-09-05
IL205265A (en) 2017-01-31
AU2010201389A1 (en) 2010-04-29
EP1581649B1 (en) 2011-01-26
ATE496938T1 (de) 2011-02-15
TWI328456B (en) 2010-08-11
EP2272864A2 (en) 2011-01-12
EA200501000A2 (ru) 2006-06-30
KR101304718B1 (ko) 2013-09-05
JP2006524034A (ja) 2006-10-26
KR20120037517A (ko) 2012-04-19
KR20120060250A (ko) 2012-06-11
EA200501000A3 (ru) 2007-04-27
JP2010193888A (ja) 2010-09-09
CA2510893A1 (en) 2004-07-15
KR20150107899A (ko) 2015-09-23
US20090227517A1 (en) 2009-09-10
US20100330072A1 (en) 2010-12-30
WO2004058988A3 (en) 2007-11-15
CN101287484B (zh) 2012-10-10
ES2359562T3 (es) 2011-05-24
US8920798B2 (en) 2014-12-30
MXPA05006521A (es) 2005-08-26
WO2004058988A2 (en) 2004-07-15
AR042545A1 (es) 2005-06-22
AR097588A2 (es) 2016-03-23
US8071538B2 (en) 2011-12-06
CN101287484A (zh) 2008-10-15
KR20150013350A (ko) 2015-02-04
SI1581649T1 (sl) 2011-09-30
EA009056B1 (ru) 2007-10-26
EP1581649A2 (en) 2005-10-05
NO20053545D0 (no) 2005-07-19
RS52815B (sr) 2013-10-31
US7803923B2 (en) 2010-09-28
US20090220491A1 (en) 2009-09-03
AU2003301195A1 (en) 2004-07-22
HK1084419A1 (en) 2006-07-28
IL169168A0 (en) 2007-07-04
NO20053545L (no) 2005-09-08
NO335982B1 (no) 2015-04-13
ZA200505481B (en) 2008-01-30
KR20050091015A (ko) 2005-09-14
IL205266A0 (en) 2011-07-31
US20040181033A1 (en) 2004-09-16
BR0317538A (pt) 2005-11-29
NZ541253A (en) 2010-03-26
CY1111388T1 (el) 2015-08-05
US20120083442A1 (en) 2012-04-05
RS20050530A (sr) 2007-09-21
US20150175687A1 (en) 2015-06-25
TW200505474A (en) 2005-02-16
AU2003301195B2 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
ATE368042T1 (de) Cephemverbindungen
IS7471A (is) Ný efnasambönd
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DE60325448D1 (de) ste
ATE496938T1 (de) Myostatin hemmende bindungsstoffe
IS7879A (is) Ný efnasambönd
DK3473251T3 (da) Nikotin-cellulose-kombination
IS7381A (is) Efnasambönd
NO20044046L (no) Substituerte hydroksyetylaminer
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20045659L (no) Forbindelser
IS7793A (is) Nýtt efnasamband
IS7827A (is) Ný efnasambönd
IS7794A (is) Nýtt efnasamband
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
IS8089A (is) Efnasambönd
DE60334042D1 (de) Drehgeber
DE60328488D1 (de) Ng
NO20031736D0 (no) Forbindelser
DE50306228D1 (de) Substituierte benzdioxepine
AT5889U3 (de) Brennholzspleisser
SE0203348D0 (sv) Novel compounds
SE0200117D0 (sv) Novel compounds
SE0200118D0 (sv) Novel compounds
SE0201636D0 (sv) Novel compounds